Literature DB >> 8027173

The types II and III transforming growth factor-beta receptors form homo-oligomers.

Y I Henis1, A Moustakas, H Y Lin, H F Lodish.   

Abstract

Affinity-labeling experiments have detected hetero-oligomers of the types I, II, and III transforming growth factor beta (TGF-beta) receptors which mediate intracellular signaling by TGF-beta, but the oligomeric state of the individual receptor types remains unknown. Here we use two types of experiments to show that a major portion of the receptor types II and III forms homo-oligomers both in the absence and presence of TGF-beta. Both experiments used COS-7 cells co-transfected with combinations of these receptors carrying different epitope tags at their extracellular termini. In immunoprecipitation experiments, radiolabeled TGF-beta was bound and cross-linked to cells co-expressing two differently tagged type II receptors. Sequential immunoprecipitations using anti-epitope monoclonal antibodies showed that type II TGF-beta receptors form homo-oligomers. In cells co-expressing epitope-tagged types II and III receptors, a low level of co-precipitation of the ligand-labeled receptors was observed, indicating that some hetero-oligomers of the types II and III receptors exist in the presence of ligand. Antibody-mediated cross-linking studies based on double-labeling immunofluorescence explored co-patching of the receptors at the cell surface on live cells. In cells co-expressing two differently tagged type II receptors or two differently tagged type III receptors, forcing one receptor into micropatches by IgG induced co-patching of the receptor carrying the other tag, labeled by noncross-linking monovalent Fab'. These studies showed that homo-oligomers of the types II and III receptors exist on the cell surface in the absence or presence of TGF-beta 1 or -beta 2. In cells co-expressing types II and III receptors, the amount of heterocomplexes at the cell surface was too low to be detected in the immunofluorescence co-patching experiments, confirming that hetero-oligomers of the types II and III receptors are minor and probably transient species.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027173      PMCID: PMC2120107          DOI: 10.1083/jcb.126.1.139

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  55 in total

1.  Cloning and sequencing of a rat type II activin receptor.

Authors:  H Shinozaki; I Ito; Y Hasegawa; K Nakamura; S Igarashi; M Nakamura; K Miyamoto; Y Eto; Y Ibuki; T Minegishi
Journal:  FEBS Lett       Date:  1992-11-02       Impact factor: 4.124

2.  daf-1, a C. elegans gene controlling dauer larva development, encodes a novel receptor protein kinase.

Authors:  L L Georgi; P S Albert; D L Riddle
Journal:  Cell       Date:  1990-05-18       Impact factor: 41.582

3.  Transforming growth factor-beta inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor.

Authors:  F T Boyd; J Massagué
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

4.  Preparation of F(ab')2 fragments from monoclonal mouse IgG1 suitable for use in radioimaging.

Authors:  R Kurkela; L Vuolas; P Vihko
Journal:  J Immunol Methods       Date:  1988-06-13       Impact factor: 2.303

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor.

Authors:  K Tsuchida; L S Mathews; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

7.  Transforming growth factor-beta (TGF-beta)-resistant helper T lymphocyte clones show a concomitant loss of all three types of TGF-beta receptors.

Authors:  C Siepl; U V Malipiero; A Fontana
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

8.  Characterization of transforming growth factor-beta (TGF-beta) receptors on BeWo choriocarcinoma cells including the identification of a novel 38-kDa TGF-beta binding glycoprotein.

Authors:  E J Mitchell; K Lee; M D O'Connor-McCourt
Journal:  Mol Biol Cell       Date:  1992-11       Impact factor: 4.138

9.  The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand.

Authors:  A Moustakas; H Y Lin; Y I Henis; J Plamondon; M D O'Connor-McCourt; H F Lodish
Journal:  J Biol Chem       Date:  1993-10-25       Impact factor: 5.157

10.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.

Authors:  G I Evan; G K Lewis; G Ramsay; J M Bishop
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

View more
  54 in total

1.  Mechanisms of transforming growth factor-beta receptor endocytosis and intracellular sorting differ between fibroblasts and epithelial cells.

Authors:  J J Doré; D Yao; M Edens; N Garamszegi; E L Sholl; E B Leof
Journal:  Mol Biol Cell       Date:  2001-03       Impact factor: 4.138

2.  Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions.

Authors:  Thomas B Thompson; Teresa K Woodruff; Theodore S Jardetzky
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

3.  Coated pit-mediated endocytosis of the type I transforming growth factor-β (TGF-β) receptor depends on a di-leucine family signal and is not required for signaling.

Authors:  Keren E Shapira; Avner Gross; Marcelo Ehrlich; Yoav I Henis
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

4.  Betaglycan has multiple binding sites for transforming growth factor-beta 1.

Authors:  S Kaname; E Ruoslahti
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

5.  Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors.

Authors:  M Kawabata; H Inoue; A Hanyu; T Imamura; K Miyazono
Journal:  EMBO J       Date:  1998-07-15       Impact factor: 11.598

6.  Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Authors:  Eyal Kalo; Yosef Buganim; Keren E Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I Henis; Varda Rotter
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

7.  Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors.

Authors:  Maya Mouler Rechtman; Alex Nakaryakov; Keren E Shapira; Marcelo Ehrlich; Yoav I Henis
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

8.  Transforming growth factor-beta type-II receptor signalling: intrinsic/associated casein kinase activity, receptor interactions and functional effects of blocking antibodies.

Authors:  F L Hall; P D Benya; S R Padilla; D Carbonaro-Hall; R Williams; S Buckley; D Warburton
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

9.  Reconstitution of a pentameric complex of dimeric transforming growth factor beta ligand and a type I, II, III receptor in baculoviral-infected insect cells.

Authors:  K Matsuzaki; M Kan; W L McKeehan
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-06       Impact factor: 2.416

10.  Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain.

Authors:  Yaniv Malka; Tekla Hornakova; Yohan Royer; Laurent Knoops; Jean-Christophe Renauld; Stefan N Constantinescu; Yoav I Henis
Journal:  J Biol Chem       Date:  2008-10-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.